Mouth Cancer Surgeons
Oral Cancer & Maxillofacial Surgery
Oral Cancer & Maxillofacial Surgery
MDS – Oral & Maxillofacial Surgery, Fellowship in Head & Neck Surgical Oncology, Consultant
Medically written and reviewed by: Dr. Pradeep S., MDS (Oral & Maxillofacial Surgery), Fellowship in Head & Neck Surgical Oncology, Apollo Hospitals Chennai
This guide provides evidence-based educational information only. It does not replace personalised medical advice. Every oral cancer case is unique — treatment decisions require assessment by a qualified maxillofacial surgeon or head and neck oncologist who can evaluate your specific findings, test results, health, and circumstances.
AI tools assisted with drafting and research organisation. All medical facts, clinical recommendations, statistics, and treatment protocols were independently verified and approved by Dr. Pradeep S., MDS (Oral & Maxillofacial Surgery), Fellow head and neck oncology, Apollo Hospitals Chennai, as of February 2026. The medical reviewer takes full clinical responsibility for the accuracy of this content.
Surgery is the primary treatment for most oral cancers. It involves removing the tumour with a safe margin of healthy tissue around it, managing the lymph nodes in the neck, and rebuilding the affected area. After surgery, radiation therapy or chemotherapy may be added — especially for advanced cancers or when the pathology report shows concerning features. Immunotherapy has recently been shown to improve outcomes when combined with standard treatment. The right plan for you depends on your tumour’s stage, location, your overall health, and your preferences.
Early-stage oral cancer has 70–90% five-year survival rates with appropriate treatment.
If you or someone you love has just been told they might have oral cancer, it is completely normal to feel overwhelmed, frightened, and uncertain about what happens next. This guide was written to help you understand every step — from what oral cancer is and how it is diagnosed, through to surgery, reconstruction, recovery, and life afterwards. You will also find practical information about costs, getting to Chennai, and questions to ask your surgeon.
Oral cancer refers to any malignant (cancerous) growth inside the mouth. This includes the tongue, the inner lining of the cheeks (called the buccal mucosa), the floor of the mouth under the tongue, the gums, the hard palate (roof of the mouth), and the ridges of the jaw where teeth sit.According to GLOBOCAN 2020 data, oral cancer represents approximately 30% of all cancers in India, with an estimated 135,000 new cases diagnosed every year — one of the highest rates in the world. Understanding why this happens in India helps explain why early detection and specialist treatment are so important.
India accounts for nearly one-third of global oral cancer cases. The main reasons are:
India has over 267 million tobacco users. Products like gutka, khaini, zarda, and betel quid with tobacco are kept in the mouth for long periods, exposing the lining of the cheek and gum directly to cancer-causing substances. A large study published in The Lancet Oncology found that chewing tobacco with betel quid increased oral cancer risk nearly eight times. The World Health Organization classifies betel quid with tobacco as a definite cause of cancer in humans.
Studies show that 60–70% of oral cancer patients in India are diagnosed at an advanced stage (Stage III or IV) — much higher than in many other countries. This happens because of delayed specialist consultation, limited health literacy, and geographic distance from tertiary care centres. Later diagnosis means harder treatment and lower survival. This is why recognising warning signs early is so critical.
Emerging research suggests that tobacco-related oral cancers in Indian patients have different genetic characteristics compared to the HPV-related throat cancers more common in Western countries. This has implications for how treatments are selected and developed.
Learn more:
Tobacco & Alcohol and Oral Cancer Risk | HPV and Oral Cancer
Oral cancer rates vary across Indian states. Western and Central India (Gujarat, Madhya Pradesh) have the highest rates among men, linked to gutka and betel quid chewing. Northeastern states like Meghalaya have the highest rates among women. Kerala, despite being a southern state, has comparatively lower smokeless tobacco use and correspondingly lower rates.
Chennai’s role as a referral centre: Apollo Hospitals Chennai and other major centres receive patients from across Tamil Nadu, states like West Bengal and Assam, and from international locations including Bangladesh, because of their experienced surgical teams, advanced reconstruction capabilities, and comprehensive support services.
The specific location of a cancer inside the mouth matters enormously — it determines symptoms, how the cancer spreads, what surgery is required, and what the outlook is likely to be.
Buccal mucosa (inner cheek) is the most common site in Indian patients, accounting for 40–50% of cases. This is directly linked to the habit of keeping tobacco or betel quid against the cheek. These cancers often appear as non-healing sores or growths and may involve the groove between the cheek and gum.
Tongue — typically the side (lateral border) or the underside (ventral surface) of the mobile part of the tongue. Tongue cancers are often caught earlier than other sites because changes in tongue movement affect speech and swallowing. However, they are more likely to spread to neck lymph nodes than cancers at some other sites.
Floor of mouth — the horseshoe-shaped area beneath the tongue. These cancers can be difficult to spot initially but often grow deeply, sometimes involving the jawbone or tongue musculature.
Gingivobuccal sulcus — the groove where the cheek meets the gum — another common site in Indian patients associated with tobacco placement.
Other sites include the hard palate (roof of the mouth), the upper and lower gum ridges (alveolus), and the retromolar trigone (the area behind the last molar tooth).
Learn more:
Tongue Cancer | Buccal Mucosa Cancer | Floor of Mouth Cancer | Gingivobuccal Sulcus Cancer | Hard Palate Cancer | Retromolar Trigone Cancer | Upper Alveolus Cancer | Lower Alveolus Cancer
Oral squamous cell carcinoma (OSCC) accounts for approximately 90–95% of all oral cancers. It arises from the flat cells lining the inside of the mouth. Under the microscope, it is classified as well-differentiated (looks closest to normal cells), moderately differentiated (intermediate), or poorly differentiated (looks very different from normal cells and tends to be more aggressive).
Verrucous carcinoma is a slower-growing, warty-looking variant of squamous cell carcinoma. It rarely spreads and usually responds well to surgery alone.
Minor salivary gland cancers arise from the many small salivary glands in the mouth lining, most densely found in the palate. The two most common types are mucoepidermoid carcinoma and adenoid cystic carcinoma. Adenoid cystic carcinoma is known for growing along nerve pathways and for the risk of very late distant spread — sometimes many years after treatment.
Oral melanoma is rare but occurs with higher relative frequency in Indian and Asian patients compared to other populations. It typically appears on the palate or upper gum, and unfortunately carries a poor outlook even with treatment.
Accurate tissue diagnosis through biopsy is essential — different cancer types require completely different treatment approaches.
Early detection dramatically improves survival. A cancer found at Stage I has a five-year survival rate of 80–90%. The same cancer found at Stage IV falls to 15–55% depending on extent. Knowing what to look for could save your life or someone else’s.
Any sore or ulcer inside the mouth that has not healed after three weeks should be seen by a specialist. This is because harmless traumatic ulcers from a sharp tooth, denture, or bite typically heal within 7–14 days. An ulcer that persists beyond three weeks needs evaluation — and possibly a biopsy.
Leukoplakia is a white patch in the mouth that cannot be rubbed off and has no other explanation. It affects 2–3% of adults. Most are harmless, but some carry risk of becoming cancerous — particularly non-homogeneous (mixed red-white, speckled, or nodular) leukoplakia and patches on the floor of the mouth, underside of tongue, or soft palate. All leukoplakia should be assessed by a specialist.
Erythroplakia is a red, velvety patch. It is less common than leukoplakia but far more dangerous — studies show 80–90% of erythroplakia lesions already contain severe dysplasia (pre-cancer) or invasive cancer at the time of first biopsy. Any red patch in the mouth warrants urgent biopsy.
Learn more:
For people at higher risk — those who currently use tobacco, betel nut, or areca nut, or drink alcohol heavily — expert consensus recommends a visual examination of the mouth every 6–12 months, usually during dental visits.
A landmark clinical trial carried out in Kerala, India, published in The Lancet (Sankaranarayanan et al., 2005), showed that screening by trained health workers reduced oral cancer deaths by 34% in high-risk individuals over a 15-year follow-up period. This is Level I evidence (the highest quality) supporting targeted screening.
Accurate diagnosis and staging are the foundation of your treatment plan. This section explains the key steps your medical team will take and what the results mean.
A biopsy is the removal of a small piece of tissue for examination under a microscope. It is the only way to confirm whether something is cancer, what type it is, and how aggressive it appears. For most suspicious areas, an incisional biopsy (taking a representative sample) is performed. For small lesions under 1cm, the entire lesion may be removed at the same time (excisional biopsy).
Learn more:
Oral Cancer Biopsy: How It’s Done and What to Expect | Understanding Your Pathology Report
Staging tells doctors — and you — how far the cancer has spread. It guides every decision about treatment and gives the most reliable information about outlook. The system used worldwide is called the TNM system, from the American Joint Committee on Cancer (AJCC).
T — Tumour: How large is the primary tumour, and how deeply has it grown into the tissues? N — Nodes: Has cancer spread to nearby lymph nodes in the neck? M — Metastasis: Has cancer spread to distant parts of the body (for example, the lungs or liver)?
These three components are combined into an overall Stage (I through IVB), with Stage I being the earliest and Stage IVB the most advanced.
Depth of invasion — why it matters more than surface size. Research has shown that how deeply a tumour penetrates into the tissue beneath it is a better predictor of lymph node spread and survival than the surface size of the tumour alone. A tumour that has invaded more than 5mm deep carries a significantly higher risk of microscopic cancer having already reached the neck lymph nodes — even when those nodes feel and look normal on imaging.
Stage | Approximate 5-Year Survival |
Stage I | 80–90% |
Stage II | 70–80% |
Stage III | 60–70% |
Stage IVA | 40–55% |
Stage IVB | 15–30% |
Important context: These are population averages across thousands of patients. They do not predict what will happen in your individual case. Your specific tumour characteristics, overall health, surgical margin status, lymph node findings, completion of recommended treatment, and tobacco cessation all influence your individual outlook — sometimes substantially. Your oncologist will discuss your personalised prognosis based on your specific situation.
Learn more:
Oral Cancer Staging Explained (TNM System) | Stage I vs Stage IV Oral Cancer | Clinical vs Pathological Staging | T Category in Oral Cancer | N Category in Oral Cancer | M Category in Oral Cancer | Depth of Invasion (DOI) in Oral Cancer | Pathological TNM (pTNM) Explained
CT scan (contrast-enhanced): Gives detailed pictures of bone involvement and enlarged lymph nodes. This is usually the first imaging test ordered.
MRI scan: Provides superior detail of soft tissue — muscles, nerves, and how deeply the tumour has grown. MRI can estimate depth of invasion before surgery, though it tends to slightly overestimate this measurement compared to what the pathologist finds under the microscope after surgery.
PET-CT scan: Combines a metabolic scan with anatomical imaging. Particularly useful for advanced-stage cancers to check whether the disease has spread elsewhere in the body, and to find any second cancers that may have developed simultaneously.
Learn more:
Imaging for Oral Cancer (CT, MRI, PET-CT): What Each Scan Shows
After surgery, the removed tissue is sent to a pathologist — a specialist doctor who examines it under a microscope. Their report contains information that determines whether you need further treatment. This section explains each key feature in plain language.
Surgical margins — did the surgeon get it all? The “margin” is the edge of the tissue that was removed. If the pathologist finds cancer cells at the very edge (called a positive margin), it means cancer may have been left behind. If the edge is clear of cancer cells by a distance of 5mm or more, this is considered a safe margin and significantly reduces the risk of the cancer coming back in the same place.
Depth of invasion (DOI) — how deep did it grow? This measures how far the cancer has penetrated downward from the surface. Deeper invasion — typically more than 3–4mm — means a higher chance that microscopic cancer cells have already reached the neck lymph nodes, even if those lymph nodes looked normal on scans. This is one of the main reasons doctors may recommend neck lymph node surgery even when the neck appears clear.
Perineural invasion (PNI) — did cancer grow along nerves? When cancer cells travel along the pathways of nerves, this is called perineural invasion. Think of it as cancer “hitchhiking” along nerve pathways to reach other areas. It signals more aggressive disease and typically means radiation therapy will be recommended after surgery — even in cases that might otherwise not need it.
Lymphovascular invasion (LVI) — did cancer enter blood or lymph vessels? If cancer cells are found inside blood vessels or lymphatic channels in the removed tissue, this means the cancer has accessed the body’s internal transport system. This significantly increases the risk that cancer has already reached the neck lymph nodes and usually favours additional treatment.
Worst pattern of invasion (WPOI-5) — how does the cancer edge behave? Pathologists look at the edge of the tumour to see whether it grows as one cohesive mass or as scattered satellite clusters. When clusters of cancer cells are scattered more than 1mm away from the main tumour edge (called WPOI-5), this is a strong predictor that the cancer may come back in the neck — even when lymph nodes appear normal. Multiple concerning pathology features together substantially increase recurrence risk.
Lymph node findings — what the nodes show If lymph nodes were removed during surgery, each one is examined. Factors that affect prognosis and treatment include: how many nodes contain cancer, which levels of the neck they are in (lower neck nodes indicate more advanced spread), the ratio of cancerous to total nodes examined, and whether cancer has broken through the node’s outer capsule.
Extranodal extension (ENE) — cancer breaking through a lymph node This is one of the most important findings in the pathology report. When cancer breaks through the outer wall of a lymph node into the surrounding tissue, it is called extranodal extension. This finding, along with positive surgical margins, is one of only two pathology results that automatically means chemotherapy will be added to the post-surgical radiation. This is based on landmark clinical trials (RTOG 9501 and EORTC 22931) that proved the combination significantly improves outcomes.
Tumour grade — how abnormal do the cells look? Well-differentiated cancer cells look fairly similar to normal cells and tend to grow more slowly. Poorly differentiated cells look highly abnormal and tend to be more aggressive. While grade provides useful information, it is less predictive of outcome than the specific features above.
Learn more:
Understanding Your Pathology Report | Positive vs Close Margin Explained | Depth of Invasion (DOI) in Oral Cancer | Perineural Invasion Explained | Lymphovascular Invasion Explained | Extranodal Extension (ENE) Explained | Tumor Grading in Oral Cancer | Pathological TNM (pTNM) Explained
Surgery is the cornerstone of oral cancer treatment. Multiple large clinical trials and systematic reviews establish it as the primary treatment for oral cavity squamous cell carcinoma that can be removed surgically. Unlike some throat cancers (oropharyngeal cancers) where radiation alone may be the preferred approach, the anatomy and spread patterns of oral cavity cancers make surgery the most effective primary treatment.
Complete removal of the tumour with an adequate margin of healthy tissue around it, appropriate management of the lymph nodes in the neck, and functional reconstruction when needed — all while minimising complications.
The most important technical goal of surgery is removing all the cancer with an adequate margin of healthy tissue around it. Studies consistently show that tumours removed with clear margins (cancer cells at least 5mm from the cut edge) have significantly lower rates of local recurrence than those with close or positive margins — regardless of what further treatment is given afterwards. The depth margin (how much healthy tissue is beneath the removed tumour) is often as important as the surface margin.
During surgery, your surgeon may send small tissue samples from the operation edges to the laboratory for rapid analysis — called a frozen section. This allows real-time feedback during the operation about whether the margins appear clear.
Learn more:
Oral Cancer Surgery Overview: What to Expect | Wide Local Excision: How Tumours Are Removed | Surgical Margins in Oral Cancer: Achieving Clear Margins | Frozen Section Analysis | Mandibulectomy: Marginal vs Segmental
One of the most important decisions in oral cancer treatment is what to do about the lymph nodes in the neck — even when scans and physical examination show the neck appears clear of cancer.
Cancer cells can spread from a mouth tumour to the lymph nodes in the neck — sometimes in numbers too small to be detected by any scan. Studies show that microscopic cancer in neck lymph nodes (called occult metastasis) is present in 20–40% of patients whose neck appears completely normal on all imaging. If these microscopic deposits are left untreated, they will grow and become a major problem.
When the risk of microscopic spread is high enough (generally when the primary tumour has invaded more than 3–4mm deep, or when other high-risk features are present), surgeons recommend removing lymph node groups from the neck at the same time as the primary surgery. This is called an elective neck dissection.
A landmark clinical trial by D’Cruz et al. — one of the most important oral cancer surgery trials — demonstrated that elective neck dissection significantly improved both disease-free survival and overall survival in early-stage oral cancer compared to a “watch and wait” approach.
Evidence-based indications for elective neck dissection include tumour depth of invasion greater than 3–4mm, poor tumour differentiation, presence of lymphovascular or perineural invasion, and cancers of the posterior tongue or floor of mouth, which have higher rates of lymph node spread.
Learn more:
Neck Dissection Explained: Types and Recovery | Elective vs Therapeutic Neck Dissection: When Each Is Needed
For many patients, the most worrying question is not just whether the cancer can be removed, but what they will look and feel like afterwards — whether they will be able to speak, eat, and swallow. Reconstruction has transformed outcomes in oral cancer surgery, and the range of options available at high-volume centres today is remarkable.
The appropriate reconstruction depends on how much tissue was removed, where in the mouth it was, and whether any bone was involved.
Small removals may heal naturally on their own, or be closed directly by stitching the edges together (primary closure), with minimal impact on function.
When significant tissue has been removed — particularly from the tongue, floor of mouth, or cheeks, or when bone has been taken — the gold standard is microvascular free flap reconstruction. This technique takes tissue from another part of your body (the donor site), brings it up to the mouth with its own blood supply, and connects the blood vessels under a microscope. At experienced high-volume centres, success rates are high.
Radial forearm free flap: Thin, flexible skin and tissue from the forearm, based on the radial artery. This is the most commonly used flap for tongue, floor of mouth, and cheek reconstruction because it is pliable and reliable. There will be a scar on the forearm (the donor site).
Fibula free flap: Bone from the lower leg, used to rebuild the jawbone (mandible) when it has been partially removed. The fibula can be shaped to match the jaw’s curve and can even be used later as the foundation for dental implants, restoring the ability to chew.
Anterolateral thigh flap: A larger amount of tissue from the thigh, suitable for big defects with significant volume loss. The thigh scar is relatively hidden.
Pectoralis major pedicled flap: A flap from the chest wall that stays connected to its original blood supply. While mostly replaced by free flaps in modern practice at tertiary centres, it remains useful for patients whose other health conditions make a lengthy microvascular operation inadvisable, or for salvage situations.
Appropriate reconstruction significantly improves speech and swallowing outcomes compared to leaving large defects to heal without rebuilding. However, the extent of the original resection is the strongest determinant of functional outcome — larger resections result in more functional change regardless of reconstruction. Your speech therapist and swallow therapist are essential members of your recovery team.
Learn more:
Reconstruction Options After Oral Cancer Surgery | Microvascular Surgery Explained: Free Flaps | Radial Forearm Free Flap: Procedure and Donor Site | Fibula Free Flap: Mandibular Reconstruction | PMMC Flap | Mandibular Reconstruction with Plate | Tongue Reconstruction | Donor Site Morbidity: What to Expect | Dental Rehabilitation After Jaw Surgery | Implant Placement After Cancer Surgery | Jaw Function After Reconstruction
Radiation therapy uses high-energy X-rays to destroy any remaining cancer cells. When given after surgery, it is called adjuvant radiation — “adjuvant” simply means “additional” or “supporting.” For many patients, surgery alone is not enough, and radiation is needed to reduce the risk of the cancer coming back.
Your oncology team will recommend radiation therapy after surgery if any of the following are present in your pathology report or clinical assessment:
These two findings (extranodal extension and positive margins) are the highest-risk features in oral cancer pathology, and landmark trials (RTOG 9501 and EORTC 22931) proved that adding chemotherapy to radiation significantly improves outcomes in these situations.
IMRT (Intensity-Modulated Radiation Therapy): Modern computer-guided radiation that shapes the beam precisely around the tumour area, sparing nearby healthy structures like salivary glands and swallowing muscles. IMRT has significantly reduced side effects compared to older radiation techniques, particularly dry mouth and swallowing difficulty.
VMAT (Volumetric-Modulated Arc Therapy, including RapidArc): An advanced form of IMRT where the radiation beam rotates continuously around the patient. Studies show VMAT further reduces severe swallowing and dry mouth side effects compared to conventional IMRT, while delivering excellent tumour coverage.
Helical Tomotherapy: Delivers radiation using a CT scanner-like rotating gantry, providing highly precise dose delivery especially useful for complex head and neck cases.
Proton Therapy: The most advanced approach to sparing healthy tissue. Proton beams deposit their maximum energy precisely at the tumour depth, with virtually no radiation beyond the target. A large analysis of 580 patients showed that proton therapy resulted in 22% severe acute toxicity versus 45% with IMRT, with improved patient-reported outcomes in swallowing, dry mouth, pain, and speech. Apollo Proton Cancer Centre in Chennai offers this technology.
Learn more:
Radiation After Oral Cancer Surgery | Concurrent Chemoradiation Explained | Managing Radiation Side Effects | Radiation Planning Process Explained
Chemotherapy drugs kill cancer cells or stop them from dividing. In oral cancer treatment, chemotherapy is rarely used alone — it is most often given alongside radiation therapy to make it more effective (concurrent chemoradiation), or occasionally used for cancer that has spread widely or cannot be operated on.
The most commonly used chemotherapy drug in this setting is cisplatin, given by intravenous drip every three weeks during radiation. It makes cancer cells more sensitive to the radiation and has been proven in multiple trials to improve tumour control when added to post-surgical radiation in high-risk disease.
Side effects of chemotherapy include nausea, kidney stress (cisplatin can affect the kidneys, which is why fluids are given carefully), hearing effects, nerve tingling in the hands and feet, hair loss (less common with cisplatin than some other drugs), and reduced blood counts increasing infection risk. Your oncology team will monitor you closely throughout.
Learn more:
Chemotherapy in Oral Cancer | Chemotherapy Side Effects Explained | Concurrent Chemoradiation Explained
Your immune system is your body’s natural defence against disease. Cancer sometimes hides from it by displaying “do not attack” signals on its surface. Immunotherapy uses medicines that remove these signals — taking the “cloak” off cancer cells — so your own immune cells can find and destroy them. This is different from chemotherapy, which attacks all fast-dividing cells throughout the body.
The two main immunotherapy drugs used in head and neck cancer are pembrolizumab (brand name: Keytruda) and nivolumab (brand name: Opdivo). Both work by blocking a protein called PD-1. Think of PD-1 as a “brake” on your immune system — these medicines release that brake, allowing immune cells to attack cancer more vigorously.
A major clinical trial called KEYNOTE-048 established pembrolizumab as a first-line treatment for patients whose head and neck cancer has come back after previous treatment or has spread to other parts of the body (recurrent or metastatic disease). It can be used either on its own or combined with chemotherapy in this setting, and it became the standard of care for advanced disease.
A landmark phase 3 clinical trial called KEYNOTE-689 — published in the New England Journal of Medicine in June 2025 and conducted across 192 centres worldwide — has changed what is possible for patients with locally advanced, resectable head and neck cancer. This is the first positive trial in this disease setting in over two decades.
What the trial tested: Whether adding pembrolizumab before and after surgery (a “perioperative” approach — “peri” means around) would improve outcomes for patients with stage III or IVA head and neck squamous cell carcinoma that could still be surgically removed.
714 patients enrolled · Median follow-up 38 months · Data cutoff July 2024 · Published NEJM June 2025
| Pembrolizumab + Standard Care | Standard Care Alone |
Cancer-free at 3 years | 57.6% | 46.4% |
Median time before any relapse | 51.8 months (~4.3 years) | 30.4 months (~2.5 years) |
For patients whose tumour had higher PD-L1 expression (CPS score 10 or above), the benefit was even more pronounced — 3-year cancer-free survival of 59.8% versus 45.9%.
What this means in plain language: Adding pembrolizumab extended the period patients remained cancer-free by approximately 21 months — from around 2.5 years to over 4 years. A significant additional finding was that patients on pembrolizumab were much more likely to show a major pathological response — meaning when the tumour was examined under the microscope after surgery, far fewer living cancer cells were found. This is a strong indicator that the treatment is actively killing the cancer.
Overall survival data are still being collected, but early trends favour pembrolizumab.
Your doctor will assess several factors before recommending immunotherapy:
Stage of cancer: The KEYNOTE-689 findings apply to stage III or IVA cancer that is still operable. For cancer that has already spread or cannot be removed, the earlier KEYNOTE-048 approvals apply.
PD-L1 test result: A lab test on your tumour tissue checks for a protein called PD-L1, reported as a Combined Positive Score (CPS). Patients with CPS ≥1 benefited from pembrolizumab; those with CPS ≥10 saw the greatest benefit. Ask your doctor whether your tumour has been tested for PD-L1.
Overall health and fitness for surgery: Immunotherapy is given alongside surgery and radiation — your team will assess whether you are fit enough for the full treatment course.
Pre-existing autoimmune conditions: Some conditions affecting the immune system may make immunotherapy riskier. Always share your full health history with your team.
Because immunotherapy activates your immune system, it can sometimes cause inflammation in normal, healthy tissues. Most people tolerate it reasonably well, and no new unexpected side effects were identified in KEYNOTE-689.
Common side effects (usually manageable): Tiredness, skin rash or itching, loose stools or diarrhoea, reduced appetite, nausea, joint or muscle aches.
Tell your care team immediately if you notice: New or worsening shortness of breath or cough, severe stomach pain or diarrhoea, yellowing of skin or eyes (which could indicate liver inflammation), a severe rash or blistering, unusual headache or vision changes, or signs of hormone imbalance such as extreme unexplained fatigue or weight change.
Immune-related side effects were more frequent with pembrolizumab than with standard care alone in KEYNOTE-689 — but were generally manageable and no new safety signals were identified. Never stop immunotherapy without first speaking to your care team.
Learn more:
For cancers classified as Stage IVA that can still be removed surgically, the approach is typically surgery with reconstruction, followed by adjuvant chemoradiation (when high-risk pathology features are present). The addition of perioperative pembrolizumab (from KEYNOTE-689) is now also an option for eligible patients.
Some Stage IVA cancers are very extensive and cannot be safely removed by surgery — these are described as “unresectable.” For unresectable locally advanced disease, the primary approach is definitive chemoradiation (radiation given together with chemotherapy as the main treatment, not after surgery).
If oral cancer comes back after initial treatment, this is called recurrent disease. It represents one of the most challenging situations in oncology.
Local recurrence — cancer returning at the original site — may be treatable with surgery if it has not previously been irradiated, or if a sufficiently long period has passed. This is called salvage surgery, and it carries greater complexity and risk of complications than the original operation.
Regional recurrence — cancer returning in the neck lymph nodes — may be amenable to further surgery if the disease is limited.
Distant recurrence — cancer spreading to the lungs, liver, or other organs — is typically managed with systemic treatment including chemotherapy, immunotherapy (pembrolizumab for eligible patients based on KEYNOTE-048 results), or clinical trial participation. The goal at this stage is often to control the disease and maintain quality of life for as long as possible.
Learn more:
Advanced Stage (Stage IV) Oral Cancer Management | Management of Recurrent Oral Cancer | Salvage Surgery in Oral Cancer | When Is Oral Cancer Considered Inoperable? | Tracheostomy in Oral Cancer Surgery
Oral cancer treatment is never managed by one doctor working alone. At leading hospitals, every new patient’s case is discussed at a multidisciplinary tumour board — a structured meeting where specialists from different fields review your scans, biopsy results, and history together before recommending a treatment plan.
Multiple studies confirm that multidisciplinary team-based care significantly improves guideline adherence, reduces treatment delays, and improves five-year survival compared to single-specialist management.
Learn more:
Multidisciplinary Tumor Board Approach | Why Choose a Maxillofacial Surgeon for Oral Cancer | Questions to Ask Your Oral Cancer Surgeon | Second Opinion for Oral Cancer
Stop tobacco immediately. Even 4–6 weeks of tobacco cessation before surgery measurably improves wound healing and significantly reduces pulmonary (breathing) complications. Continued tobacco use during and after treatment worsens outcomes at every stage — survival rates are 20–50% lower in patients who continue using tobacco compared to those who stop. Your surgical team can refer you to cessation support.
Nutrition. Malnutrition is surprisingly common in oral cancer patients at diagnosis — sometimes because the tumour itself makes eating painful or difficult. Poor nutritional status increases surgical complications. Your team will assess your nutritional status and may recommend supplements or dietary changes before your operation.
Dental assessment. If you are going to receive radiation therapy to the jaw area, certain teeth that are not restorable may need to be removed before radiation begins — ideally at least 2–3 weeks beforehand. Extracting teeth after radiation to the jaw carries a significant risk of a serious complication called osteoradionecrosis (bone that does not heal properly after radiation), so it is much safer to address dental issues beforehand.
Swallow therapy — starting early. Evidence suggests that beginning swallowing exercises before or during treatment may reduce the severity of swallowing difficulties that develop afterwards. Your speech and swallow therapist may meet with you before surgery to establish a baseline and begin preventative exercises.
Learn more:
Hospital stay: Simple excision without reconstruction: 5–7 days. Complex surgery with microvascular free flap reconstruction: 2–3 weeks.
Return to activities: Most patients can resume normal daily activities 4–6 weeks after discharge, though this varies with surgical complexity.
Functional recovery: Complete recovery of speech and swallowing after extensive surgery takes 6–12 months, with ongoing improvement sometimes continuing beyond the first year. Active engagement in rehabilitation is crucial — the more you practise the exercises your therapist gives you, the better your functional outcomes.
Swallowing difficulty (called dysphagia) affects 40–60% of oral cancer patients after treatment. In severe cases, aspiration — food or liquid entering the airway instead of the food pipe — can lead to pneumonia, which is a significant long-term risk. Speech and swallowing therapy is not optional: it is a critical part of your recovery.
Your speech-language pathologist will work with you on exercises to strengthen swallowing muscles, teach compensatory swallowing techniques (such as chin tuck or head rotation), and conduct objective swallowing assessments (modified barium swallow study) to guide your programme.
Learn more:
Speech & Swallowing Rehabilitation After Oral Cancer | Life After Oral Cancer Surgery | Jaw Mobility Exercises After Surgery | Recovery Timeline After Oral Cancer Surgery | Expected Hospital Stay After Oral Cancer Surgery
Malnutrition during treatment is common and makes everything harder — it increases complications, can cause treatment to be delayed or reduced, and is associated with worse survival. Your dietitian will calculate your individual energy and protein needs and help you meet them through food, nutritional supplements, or if necessary, a feeding tube.
If swallowing becomes severely impaired during treatment, a feeding tube (either through the nose — nasogastric — or directly into the stomach — gastrostomy/PEG tube) may be placed temporarily to ensure you receive adequate nutrition. Most patients who need a tube during radiation are able to eat normally again once the acute effects of treatment settle.
Radiation to the jaw causes dry mouth (xerostomia) in 80–90% of patients because salivary glands are affected. Without adequate saliva, tooth decay progresses very rapidly and affects unusual tooth surfaces. Meticulous daily dental care and fluoride gel application (1.1% sodium fluoride in custom trays) are essential after radiation.
Osteoradionecrosis — exposed, non-healing bone in the irradiated jaw — is a serious but preventable complication, affecting approximately 2–22% of patients depending on radiation dose and other factors. Prevention strategies include addressing all dental problems before radiation, maintaining excellent oral hygiene, and avoiding dental extractions after radiation wherever possible.
A cancer diagnosis and major treatment affect the mind as well as the body. Anxiety, depression, changes in self-image after surgery or radiation, and fear of recurrence are all common and entirely understandable. These are not weaknesses — they are normal human responses to an enormously difficult experience.
Psychological support is available and effective. Ask your care coordinator about psycho-oncology services at Apollo Hospitals Chennai. Peer support groups — connecting with others who have been through similar experiences — can also be profoundly helpful. You do not have to face this alone.
Most oral cancer recurrences happen within the first two years. Your follow-up schedule is designed accordingly — more frequent visits early on, tapering over time.
Each visit includes a clinical examination, assessment of rehabilitation progress, and evaluation of treatment-related late effects. Imaging is ordered based on clinical findings or symptoms — a baseline PET-CT at approximately 12 weeks after completing treatment is recommended for high-risk patients to distinguish residual tumour from post-treatment tissue changes.
Patients who have used tobacco or alcohol should expect surveillance to continue beyond five years — the risk of a second primary cancer (a new, separate cancer developing in the mouth, throat, or lungs) is 3–7% per year in continued users.
Learn more:
Follow-Up & Recurrence Monitoring | Recurrence After Oral Cancer Treatment | Local vs Regional Recurrence Explained | Long-Term Outcomes After Treatment | Oral Cancer Prognosis & Survival Rates | 5-Year Survival in Oral Cancer | Factors Affecting Oral Cancer Survival
There is no single fixed price for oral cancer treatment — costs vary significantly based on the extent of your disease and what treatment you need. Factors that affect costs include:
Learn more:
Private health insurance typically covers oral cancer treatment, subject to policy terms. Key things to check with your insurer before treatment:
Apollo Hospitals Chennai has a dedicated insurance desk that can assist with pre-authorisation, documentation, and cashless claim processing for network policies.
Learn more:
Traveling to Chennai for Oral Cancer Treatment | Pre-Surgery Evaluation for Outstation Patients | Post-Surgery Follow-Up for Outstation Patients | International Patients at Chennai: What to Expect | Visa & Medical Travel Guidance for International Patients
Quick answer: Hospital stay ranges from 5–7 days for simpler surgery to 2–3 weeks for complex reconstruction. Most patients return to normal activities 4–6 weeks after discharge. Complete functional recovery of speech and swallowing after extensive surgery takes 6–12 months.
After discharge, your recovery depends on extent of surgery, whether you had any complications, your nutritional status, and how actively you engage in rehabilitation. If radiation therapy follows surgery, allow a further 6–7 weeks of daily treatment, with acute effects settling over 2–3 months. Some late radiation effects — particularly dry mouth — may be longer-lasting.
Learn more:
Recovery Timeline After Oral Cancer Surgery | Expected Hospital Stay After Oral Cancer Surgery
Quick answer: Early-stage oral cancer has 70–90% five-year survival rates with appropriate treatment. Advanced disease has 30–55% survival depending on specific factors. Your individual prognosis depends on multiple factors your oncologist will discuss.
“Cure” in oncology means achieving durable remission — no evidence of disease that is likely to stay away. The majority of recurrences happen within the first 2–3 years; patients who remain disease-free beyond five years have progressively lower recurrence risk. Tobacco cessation after diagnosis substantially improves survival.
Learn more:
Oral Cancer Prognosis & Survival Rates | Factors Affecting Oral Cancer Survival | 5-Year Survival in Oral Cancer
Quick answer: During treatment: mouth sores, difficulty swallowing, taste changes, skin reactions, and fatigue. Long-term effects include dry mouth (80–90%), jaw stiffness (20–40%), and dental issues. Modern IMRT and VMAT techniques significantly reduce severity compared to older radiation methods.
Acute effects — those that happen during and immediately after radiation — generally peak around weeks 4–6 of treatment and resolve over 2–3 months. Late effects — those that develop months to years later — are more variable. Meticulous dental hygiene, daily fluoride gel, jaw exercises, and regular follow-up are essential for managing late effects.
Learn more:
Managing Radiation Side Effects
Quick answer: Yes — unequivocally. Continuing tobacco use doubles wound complications, significantly lowers treatment success rates, worsens survival by 20–50%, and maintains a 3–7% annual risk of developing a second new cancer.
Evidence is clear: patients who continue using tobacco during and after treatment have significantly worse outcomes at every measure. The benefits of stopping begin within weeks — wound healing improves, complication risk decreases, and long-term cancer risk gradually declines. Effective support is available (behavioural counselling and medication combined achieve quit rates of 20–40%). Your team can refer you to a cessation programme.
Quick answer: This depends on how much tissue was removed. Small resections: 70–85% return to a normal or near-normal diet within 2–3 months. Moderate resections: 50–70% achieve near-normal eating with some modifications. Extensive resections involving most of the tongue or multiple structures: some permanent dietary changes are likely, and a proportion of patients may need ongoing nutritional support.
Active swallow therapy significantly improves outcomes regardless of the extent of surgery. The goal is always to maximise your oral function — your speech and swallow therapist will work with you throughout.
Quick answer: Year 1: every 1–3 months. Year 2: every 2–4 months. Years 3–5: every 4–6 months. Beyond 5 years: every 6–12 months. The frequency reflects the fact that 80–90% of recurrences happen within the first 2–3 years.
Each appointment includes clinical examination, assessment of rehabilitation needs, and review of any side effects. Imaging is ordered when clinically indicated. For tobacco users, annual chest imaging to screen for lung cancer is recommended throughout follow-up.
Learn more:
Follow-Up & Recurrence Monitoring
Quick answer: Oral cancer surgery can be performed by a maxillofacial surgeon, ENT surgeon, or general surgeon — provided they have completed advanced specialised training in head and neck oncology, such as fellowship in head and neck surgical oncology or MCh in Head and Neck Oncology or Surgical Oncology. The surgeon’s training and experience matters far more than their base specialty.
When evaluating a surgeon, ask directly: What advanced training have you completed specifically in head and neck oncology? How many oral cancer resections do you personally perform per year? Do you have access to microvascular reconstruction for complex defects? Is there a formal multidisciplinary tumour board where my case will be discussed before treatment begins? A well-trained maxillofacial, ENT, or surgical oncologist operating within a full multidisciplinary team at a high-volume centre is appropriately qualified — what matters is that the surgeon has been specifically trained to remove cancer, not just to operate in the region.
Learn more:
Why Choose a Maxillofacial Surgeon for Oral Cancer | Questions to Ask Your Oral Cancer Surgeon | Second Opinion for Oral Cancer
Your first consultation with a surgeon typically lasts 30–60 minutes. The surgeon will take a detailed history of your symptoms and medical background, examine your mouth and neck carefully, review all your existing scans and biopsy reports, and explain what they found and what they recommend.
Family members and caregivers carry a significant emotional and practical burden during a patient’s cancer treatment. It is important to acknowledge and care for your own wellbeing too.
Learn more:
Medical authorship and review: Dr. Pradeep S. is a fellowship-trained maxillofacial and oral cancer surgeon with over 15 years of experience. He completed his MDS in Oral & Maxillofacial Surgery and advanced fellowship training in Head & Neck Surgical Oncology. He is a Fellow of the International Board for Certification of Specialists in OMFS – Head & Neck Surgery, and has worked across multiple cancer institutions including Apollo Proton Cancer Centre. He currently practices at Apollo Hospitals, Chennai and has published many peer-reviewed research papers in oral oncology and maxillofacial surgery.
Evidence standards: This guide synthesises evidence from Level I randomised controlled trials where available, supplemented by systematic reviews, meta-analyses, NCCN and ASCO guidelines, AJCC TNM Classification, large cancer registry databases (SEER, NCDB, NCRP India), and peer-reviewed publications in high-impact journals. All clinical recommendations align with major evidence-based head and neck oncology guidelines and represent accepted standards of care in tertiary cancer centres as of February 2026.
Content creation transparency: AI tools assisted with drafting and research organisation. All medical facts, clinical recommendations, statistics, and treatment protocols were independently verified and approved by Dr. Pradeep S., MDS (Oral & Maxillofacial Surgery), Fellow head and neck oncology, Apollo Hospitals Chennai, as of February 2026. The medical reviewer takes full clinical responsibility for the accuracy of this content.
Last comprehensive review: February 2026 Next scheduled review: February 2027 Updates cover: Changes in staging systems, new high-level evidence, updated treatment guidelines
If you have been diagnosed with oral cancer or are awaiting biopsy results, early specialist evaluation is important. To schedule a consultation with Dr. Pradeep S. at Apollo Hospitals Chennai, call +91 96633 03747 (Mon–Sat, 8 AM–8 PM), or book online at mouthcancersurgeons.com/book-appointment/.
Remember: Early detection saves lives. If you notice any warning signs, consult a specialist without delay.